Factors Influencing the Effectiveness of Prescription Weight Loss Medications

Recent research sheds light on the various factors that can impact the success of popular prescription weight loss drugs, specifically glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, known commercially as Ozempic and Wegovy. A comprehensive study published in Diabetes, Obesity and Metabolism analyzed data from 679 individuals with overweight or obesity who initiated GLP-1RA therapy between November 2022 and October 2024. The findings indicate that longer durations of medication use, particularly with semaglutide, correlate with more significant weight loss over a 12-month period. Furthermore, individuals who do not have diabetes, possess a higher percentage of body fat, or exhibit a higher metabolic rate tend to experience better results. Specific factors such as skeletal muscle mass, fat distribution in the abdomen and limbs, and serum creatinine levels were also associated with an increased likelihood of successful weight reduction. These insights could pave the way for personalized treatment strategies, optimizing weight management outcomes in patients using GLP-1RA therapy.

According to Dr. Linong Ji of Peking University People's Hospital, understanding these determinants offers valuable chances to refine approaches for weight loss in real-world settings, ultimately aiding in the development of tailored interventions for individuals battling overweight and obesity.

Source: MedicalXpress

More details in the original study